Skip to main content

Anthrax

18
Pipeline Programs
5
Companies
19
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
9
1
5
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 22 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
9 programs
5
1
1
BioThraxPhase 31 trial
BioThraxPhase 21 trial
Anthrax VaccinePhase 1Vaccine1 trial
Ciprofloxacin and ValortimPhase 11 trial
Doxycycline and ValortimPhase 11 trial
+4 more programs
Active Trials
NCT03569514Not Yet Recruiting10Est. Aug 2027
NCT05672875Terminated343Est. Apr 2023
NCT00114621Completed93Est. May 2011
+5 more trials
Emergent BioSolutions
9 programs
1
1
3
2
AV7909Phase 31 trial
BioThraxPhase 3
AV7909Phase 2
BioThraxPhase 2
Ciprofloxacin 500Mg TabletPhase 21 trial
+4 more programs
Active Trials
NCT07268612Not Yet Recruiting250Est. Nov 2037
NCT01202695Completed50Est. Jun 2011
NCT00845650Completed129Est. Oct 2010
+2 more trials
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
4 programs
2
1
rPA102Phase 21 trial
AV7909Phase 11 trial
Recombinant Protective Antigen, Anthrax Vaccine AdsorbedPhase 1Vaccine1 trial
Normal Saline for InjectionPHASE_11 trial
Active Trials
NCT01265745Completed28Est. Dec 2011
NCT04660201Completed41Est. Mar 2024
NCT00063843Completed80Est. Aug 2005
+1 more trials
BlueWillow Biologics
BlueWillow BiologicsMI - Ann Arbor
1 program
1
BW-1010: 50 µg - sprayer - INPhase 11 trial
Active Trials
NCT04148118Completed84Est. Sep 2021
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
GC1109 or Placebo of GC1109PHASE_21 trial
Active Trials
NCT01624532Completed240Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Emergent BioSolutionsAV7909
Human BioSciencesBioThrax
GC BiopharmaGC1109 or Placebo of GC1109
Emergent BioSolutionsCiprofloxacin 500Mg Tablet
Human BioSciencesBioThrax
Allergy TherapeuticsrPA102
Emergent BioSolutionsAIGIV 3.5 mg/kg
Allergy TherapeuticsAV7909
BlueWillow BiologicsBW-1010: 50 µg - sprayer - IN
Human BioSciencesPx563L, RPA563, or placebo
Allergy TherapeuticsNormal Saline for Injection
Emergent BioSolutionsAVP-21D9
Human BioSciencesCiprofloxacin and Valortim
Human BioSciencesDoxycycline and Valortim
Human BioSciencesAnthrax Vaccine

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 6,358 patients across 19 trials

NCT03877926Emergent BioSolutionsAV7909

VELOCITY: An Anthrax Vaccine Clinical Study

Start: Mar 2019Est. completion: Aug 20203,862 patients
Phase 3Completed
NCT01491607Human BioSciencesBioThrax

Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

Start: Nov 2011Est. completion: May 2012200 patients
Phase 3Completed
NCT01624532GC BiopharmaGC1109 or Placebo of GC1109

A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109

Start: Jul 2021Est. completion: Dec 2022240 patients
Phase 2Completed
NCT04067011Emergent BioSolutionsCiprofloxacin 500Mg Tablet

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

Start: Aug 2019Est. completion: Mar 2020210 patients
Phase 2Completed
NCT01753115Human BioSciencesBioThrax

Ciprofloxacin BioThrax Co-Administration Study

Start: Dec 2012Est. completion: Aug 2013154 patients
Phase 2Completed
NCT00100724Allergy TherapeuticsrPA102

Trial of rPA-102 Vaccine in Healthy Adult Volunteers

Start: Apr 2004Est. completion: Jul 2005480 patients
Phase 2Completed
NCT00845650Emergent BioSolutionsAIGIV 3.5 mg/kg

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

Start: Feb 2009Est. completion: Oct 2010129 patients
Phase 1/2Completed
NCT04660201Allergy TherapeuticsAV7909

Anthrax AV7909 Liquid vs Lyophilized

Start: May 2022Est. completion: Mar 202441 patients
Phase 1Completed
NCT04148118BlueWillow BiologicsBW-1010: 50 µg - sprayer - IN

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults

Start: Jan 2020Est. completion: Sep 202184 patients
Phase 1Completed
NCT02655549Human BioSciencesPx563L, RPA563, or placebo

A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects

Start: Dec 2015Est. completion: Jun 201754 patients
Phase 1Completed
NCT01265745Allergy TherapeuticsNormal Saline for Injection

Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects

Start: Dec 2010Est. completion: Dec 201128 patients
Phase 1Completed
NCT01202695Emergent BioSolutionsAVP-21D9

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

Start: Aug 2010Est. completion: Jun 201150 patients
Phase 1Completed
NCT00964561Human BioSciencesCiprofloxacin and Valortim

Ph1 Study of Valortim and Ciprofloxacin in Humans

Start: Aug 2009Est. completion: Jul 201026 patients
Phase 1Suspended
NCT00964834Human BioSciencesDoxycycline and Valortim

Ph1 Study of Valortim and Doxycycline in Humans

Start: Jul 2009Est. completion: Dec 200924 patients
Phase 1Terminated
NCT00114621Human BioSciencesAnthrax Vaccine

Anthrax Vaccine Clinical Trials

Start: Sep 2004Est. completion: May 201193 patients
Phase 1Completed
NCT00063843Allergy TherapeuticsRecombinant Protective Antigen, Anthrax Vaccine Adsorbed

Anthrax-rPA: Safety, Tolerability, Immunogenicity

Start: Jul 2003Est. completion: Aug 200580 patients
Phase 1Completed
NCT07268612Emergent BioSolutionsCYFENDUS

Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.

Start: Nov 2035Est. completion: Nov 2037250 patients
N/ANot Yet Recruiting
NCT03569514Human BioSciencesAIGIV

Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

Start: Nov 2026Est. completion: Aug 202710 patients
N/ANot Yet Recruiting
NCT05672875Human BioSciencesAnthrax LF Dx System

Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System

Start: Jan 2023Est. completion: Apr 2023343 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.